Jon Snodgres - 24 Feb 2022 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Reporting relationship: Chief Financial Officer
Issuer ticker: RGEN
Reported as of: 24 Feb 2022
Net transaction value: -$50,897
SEC form: 4
Accepted by SEC: 28 Feb 2022, 18:10:51 UTC
Prior SEC filing: 22 Feb 2022
Next SEC filing: 02 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Kimberly Brown (Attorney in Fact)

Key filing fact

Jon Snodgres filed Form 4 for REPLIGEN CORP (RGEN) on 28 Feb 2022.

Key facts

This page summarizes Jon Snodgres's Form 4 filing for REPLIGEN CORP (RGEN).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2022, 18:10.

Change

Previous filing in this sequence was filed on 22 Feb 2022.
Current net transaction value: -$50,897.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGEN transaction

Common Stock

Award

Transaction value: $0
Shares: +3,443
Change %: +11%
Price: $0.000000
Shares after: 33,904
Date: 24 Feb 2022
Ownership: Direct
Footnotes: F1

RGEN transaction

Common Stock

Tax liability

Transaction value: $50,897
Shares: -269
Change %: -0.79%
Price: $189.21
Shares after: 33,635
Date: 24 Feb 2022
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGEN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +4,410
Change %
Price: $0.000000
Shares after: 4,410
Date: 24 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,410
Exercise price: $189.21
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Mr. Snodgres was awarded 3,443 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Footnote F2

Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Footnote F3

One third of the stock options will vest and become exercisable annually on February 24, 2023, February 24, 2024 and February 24, 2025.